Compare Visa Inc (V) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Visa Inc vs Health Care Select Sector SPDR Fund — how do they compare? Visa Inc trades at $355.62 (market cap $685.71B), while Health Care Select Sector SPDR Fund trades at $160.19. The key difference: Visa Inc pays a 0.74% dividend while Health Care Select Sector SPDR Fund pays none. Which is the better fit depends on your goals.
| V | XLV | |
|---|---|---|
Market Cap | $685.71B | — |
Volume | 10,431,336 | — |
Sector | Financials | — |
52-Week High | $365.14 | $164.48 |
52-Week Low | $295.52 | $129.01 |
Enterprise Value | $696.30B | — |
Dividend Yield | 0.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Visa (V) trades at $355.82, down 0.76% on the day, with a bullish technical outlook supported by moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $3.31 exceeding the $3.10 estimate. Revenue growth remains robust, reaching $40B in 2025, and profitability is high with a net income margin of 51.68%. Recent news highlights Visa's focus on AI-driven commerce and stablecoin partnerships, positioning it for future payment innovations.
The stock offers a compelling long-term investment case with 85% analyst buy ratings and a $396.70 consensus price target, implying 11% upside. Key risks include competitive threats from fintech and regulatory pressures. Visa's strong cash flow and dividend payments provide shareholder value, but investors should monitor execution on AI initiatives and macroeconomic impacts on consumer spending.
XLV trades at $159.25, down 1.14% with neutral technical signals overall. The healthcare ETF shows mixed momentum with bullish moving averages but neutral oscillators. Recent news highlights XLV's defensive characteristics amid market volatility, with State Street upgrading healthcare to positive for Q3 2026. The fund's diversified approach offers stability compared to more volatile biotech-focused alternatives.
XLV presents a defensive opportunity with lower costs and steady performance, though upside may be limited in the current cycle. Key risks include patent cliff concerns and sector rotation away from defensive plays if market sentiment improves. The ETF's broad healthcare exposure provides cushion against individual stock volatility while benefiting from pipeline innovations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →About Health Care Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →
